open access

Vol 68, No 1 (2010)
Other
Published online: 2010-02-03
Submitted: 2012-12-28
Get Citation

Original article
Plasma NT-proANP in patients with persistent atrial fibrillation who underwent successful cardioversion

Radosław Bartkowiak, Beata Wożakowska-Kapłon, Grażyna Janiszewska
Kardiol Pol 2010;68(1):48-54.

open access

Vol 68, No 1 (2010)
Other
Published online: 2010-02-03
Submitted: 2012-12-28

Abstract

Background: Atrial fibrillation (AF) decreases quality of life and significantly increases risk of stroke, congestive heart failure and death. Atrial overload and stretch also result in increased production of natriuretic peptide type A (ANP). The biologically inactive prohormone NT-proANP is released to plasma in the same amounts as ANP but it has higher levels in the blood due to decreased degradation in vivo. In vitro degradation is also slower and NT-proANP may be an interesting alternative for ANP.
Aim: To evaluate NT-proANP plasma concentration in patients with persistent AF following successful cardioversion.
Methods: The study group consisted of 43 patients with persistent AF and normal left ventricular systolic function, who underwent successful electrical cardioversion (EC). The control group comprised 20 patients with sinus rhythm without a history of AF. Blood samples were collected twice, during visits 24 h before and after EC. All patients were also examined 30 days after the sinus rhythm recovery. The NT-proANP concentration was measured using an immunochemical method (ELISA).
Results: Plasma NT-proANP concentration was significantly increased in patients with persistent AF compared to the control group (4.8 ± 2.9 vs. 2.8 ± 1.2 nmol/l, p = 0.004). Plasma NT-proANP level decreased significantly after successful cardioversion (to 3.2 ± 2.4 nmol/l; p < 0.0001). There was no correlation between the baseline NT-proANP concentration and sinus rhythm maintenance during 30 days after EC.
Conclusions: Plasma NT-proANP concentration is higher in patients with persistent AF and normal left ventricular systolic function than in patients without arrhythmia. Sinus rhythm recovery due to EC leads to a decrease of plasma NT-proANP. The baseline NT-proANP level has no prognostic value for prediction of sinus rhythm maintenance during 30 days after EC.

Abstract

Background: Atrial fibrillation (AF) decreases quality of life and significantly increases risk of stroke, congestive heart failure and death. Atrial overload and stretch also result in increased production of natriuretic peptide type A (ANP). The biologically inactive prohormone NT-proANP is released to plasma in the same amounts as ANP but it has higher levels in the blood due to decreased degradation in vivo. In vitro degradation is also slower and NT-proANP may be an interesting alternative for ANP.
Aim: To evaluate NT-proANP plasma concentration in patients with persistent AF following successful cardioversion.
Methods: The study group consisted of 43 patients with persistent AF and normal left ventricular systolic function, who underwent successful electrical cardioversion (EC). The control group comprised 20 patients with sinus rhythm without a history of AF. Blood samples were collected twice, during visits 24 h before and after EC. All patients were also examined 30 days after the sinus rhythm recovery. The NT-proANP concentration was measured using an immunochemical method (ELISA).
Results: Plasma NT-proANP concentration was significantly increased in patients with persistent AF compared to the control group (4.8 ± 2.9 vs. 2.8 ± 1.2 nmol/l, p = 0.004). Plasma NT-proANP level decreased significantly after successful cardioversion (to 3.2 ± 2.4 nmol/l; p < 0.0001). There was no correlation between the baseline NT-proANP concentration and sinus rhythm maintenance during 30 days after EC.
Conclusions: Plasma NT-proANP concentration is higher in patients with persistent AF and normal left ventricular systolic function than in patients without arrhythmia. Sinus rhythm recovery due to EC leads to a decrease of plasma NT-proANP. The baseline NT-proANP level has no prognostic value for prediction of sinus rhythm maintenance during 30 days after EC.
Get Citation

Keywords

NT-proANP; atrial fibrillation; cardioversion

About this article
Title

Original article
Plasma NT-proANP in patients with persistent atrial fibrillation who underwent successful cardioversion

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 68, No 1 (2010)

Pages

48-54

Published online

2010-02-03

Bibliographic record

Kardiol Pol 2010;68(1):48-54.

Keywords

NT-proANP
atrial fibrillation
cardioversion

Authors

Radosław Bartkowiak
Beata Wożakowska-Kapłon
Grażyna Janiszewska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl